Cooperative Agreement UH3CA313817
Award Date 7/17/26
Completion Date 6/30/29
Dollars Obligated $327K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $225,511 to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. on March 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The agreement supports the development and validation of a plasma-based multimodal digital polymerase chain reaction (PCR) assay designed to detect androgen receptor (AR) somatic alterations in metastatic...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded a $690,637 Cooperative Agreement to the Beckman Research Institute of the City of Hope, effective September 1, 2025 through August 31, 2030, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). This award supports the development and validation of a blood-based biomarker test for early detection of pancreatic ductal adenocarcinoma (PDAC) utilizing 5-methylcytosine (5MC) and 5-hydroxymethylcytosine...
- Federal Cooperative Agreement Summary Mayo Clinic received a $688,661 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded June 9, 2026, with completion targeted for May 31, 2031. The research focuses on developing advanced cell-free DNA (cfDNA) analysis methodologies to prospectively detect and monitor Neurofibromatosis Type 1 (NF1) peripheral nerve sheath tumors. The project addresses a critical clinical...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded Children's Hospital of Philadelphia $427,064 on July 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct pilot and feasibility studies for a planned randomized controlled trial. This cooperative agreement supports the EDISYN (Early Detection in Syndromic Cancers) Consortium's work to evaluate the addition of circulating tumor DNA (ctDNA) screening to standard cancer screening...
- Federal Cooperative Agreement Summary The University of Michigan received a $210,600 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), effective September 1, 2025, through August 31, 2027. This award supports the analytical and clinical validation of an H3K27M circulating tumor DNA (ctDNA) assay designed to improve disease monitoring and early detection of progression in diffuse midline glioma (DMG) patients. The...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded a $360,643 Cooperative Agreement to the University of Pittsburgh (award date: September 1, 2025; completion date: August 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to conduct preanalytical validation of circulating tumor DNA (ctDNA) from surgical drain fluid (SDF) as a biomarker for postoperative minimal residual disease (MRD) in head and neck squamous cell carcinoma (HNSCC). The project...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded The Institute for Cancer Research a Cooperative Agreement totaling $263,670 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support clinical translation of a urine-based biomarker for detecting residual disease in radical cystectomy candidates. The award, effective May 1, 2026, through April 30, 2028, funds development and validation of the Noninvasive Test for Assessment of Cancerous...
- Federal Cooperative Agreement Summary The Beckman Research Institute of the City of Hope received a $738,675 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded March 16, 2026, with a completion date of February 28, 2031. The award funds development of an exosome-based liquid biopsy assay designed to enable non-invasive early detection of colorectal adenomas and cancers from a single blood draw. The research...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University $394,695 on June 17, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate computational approaches for quantifying tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) in breast cancer tissue samples. The project, which concludes May 31, 2028, addresses a critical clinical need by leveraging digital pathology and...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded a $2,054,733 Cooperative Agreement to Massachusetts General Hospital's Research Management Division, effective September 1, 2025 through August 31, 2028, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and optimization of novel chimeric antigen receptor (CAR) T cell therapy for pancreatic cancer, specifically advancing MESO-FAP CAR-TEAM cells that simultaneously target...